The role of global risk assessment in hypertension therapy.

To maximize the benefits of preventive therapy, lipid and hypertension guidelines increasingly recommend that high-risk individuals be targeted for treatment. An individual's risk of developing cardiovascular disease depends on many risk factors, such as age, sex, blood pressure, blood lipid levels, body weight, physical fitness, smoking habits and familial predisposition. Multivariable statistical models have therefore been developed to better estimate the global risk of future coronary events and stroke. A Canadian model is not currently available because a prospective cohort of sufficient size has not been followed in Canada. Therefore, global risk assessment among Canadians can only be completed using models developed in the United States or Europe. In the present review, cardiovascular risk tools are identified that may be appropriate for Canadians, including those based on the Framingham model, the Cardiovascular Life Expectancy Model, the United Kingdom Prospective Diabetes Study (UKPDS) model and the Systematic COronary Risk Evaluation (SCORE) model. The accuracy of the Framingham model and the Cardiovascular Life Expectancy Model are also evaluated using data from a small, prospective Canadian cohort. Finally, a framework is proposed to assist health care professionals in choosing the global risk tool most appropriate for their patients.

[1]  D. Maclean,et al.  Canadian heart health surveys: a profile of cardiovascular risk. Survey methods and data analysis. Canadian Heart Health Surveys Research Group. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[2]  L. Coupal,et al.  Improving the Prediction of Cardiovascular Risk: Interaction Between LDL and HDL Cholesterol , 2003, Epidemiology.

[3]  Jayanti Mukherjee,et al.  Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. , 2005, The American journal of cardiology.

[4]  R B D'Agostino,et al.  Primary and subsequent coronary risk appraisal: new results from the Framingham study. , 2000, American heart journal.

[5]  R. Holman,et al.  Erratum: The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56) (Clinical Science (2001) 101 (671-679)) , 2002 .

[6]  E. Topol,et al.  The rudimentary phase of personalised medicine: coronary risk scores , 2003, The Lancet.

[7]  L. Coupal,et al.  Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[8]  Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. , 2004 .

[9]  L. Coupal,et al.  Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? , 1995, JAMA.

[10]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[11]  K. Anderson,et al.  An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.

[12]  R. Holman,et al.  The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). , 2001, Clinical science.

[13]  R B D'Agostino,et al.  Probability of stroke: a risk profile from the Framingham Study. , 1991, Stroke.

[14]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[15]  L. Coupal,et al.  Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated? , 2000, Circulation.

[16]  R. Stevens,et al.  UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine , 2002, Stroke.

[17]  S. Straus,et al.  Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review , 2001, BMJ : British Medical Journal.

[18]  Ralph B D'Agostino,et al.  A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. , 2003, JAMA.

[19]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.

[20]  L. Coupal,et al.  Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. , 1998, Archives of internal medicine.

[21]  R. McPherson,et al.  Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[22]  D. Jacobs,et al.  Lipoprotein‐Cholesterol Distributions in Selected North American Populations: The Lipid Research Clinics Program Prevalence Study , 1980, Circulation.